LSD1-IN-26

BIOLOGICAL ACTIV	ЛТҮ			
Description	LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC ₅₀ of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC ₅₀ =1234.57 nM) and MAO-B (IC ₅₀ =3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research ^[1] .			
IC ₅₀ & Target In Vitro	LSD1 25.3 ± 1.4 nM (IC ₅₀)	MAO-A 1234.57 nM (IC ₅₀)	MAO-B 3819.27 nM (IC ₅₀)	Bcl-2
	cIAP-1	Caspase-3	Caspase-9	
	LSD1-IN-26 (compound 12u) shows the high potency against MGC-803, KYSE450 and HCT-116 cells with IC ₅₀ values of 14.3±1.18, 22.8±1.45 and 16.3±2.22 μM, respectively, which is more potent than that of GSK-LSD1 (HY-100546) (IC ₅₀ > 64 μM) and GSK-2879552 (HY-18632) (IC ₅₀ > 64 μM) ^[1] . LSD1-IN-26 (0-24 μM, 48 h) induces the accumulation of H3K4 Me1/2 and H3K9 Me2/3 and the decrease of Bcl-2 and c-IAP1 ^[1] . LSD1-IN-26 (0-24 μM, 48 h) induces apoptosis and differentiation, and inhibits migration and cell stemness ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]			
	Cell Line:	MGC-803 cells		
	Concentration:	0, 8, 16, 24 μM		
	Incubation Time:	48 h		
	Result:	Effectively up-regulated the substrate proteins of LSD1, thereby significantly increasing the expression levels of mono-/bi-methylation of H3K4 and H3K9. Dose-dependently induced the decrease of expression levels of anti-apoptotic proteins Bcl-2 and c-IAP1, and the cleavage of apoptotic executive proteins Caspase3 and Caspase9.		

REFERENCES

[1]. Ma QS, et al. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment. Eur J Med Chem. 2023 May 5;251:115228.

Product Data Sheet

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA